Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. - Wikidata - wikimedia - TriplyDB

Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.

Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.

http://www.wikidata.org/entity/Q40685677

about

The role of SPINK1 in ETS rearrangement-negative prostate cancers Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers Recurrent rearrangements in prostate cancer: causes and therapeutic potential Discovery and Classification of Fusion Transcripts in Prostate Cancer and Normal Prostate Tissue Role of the TMPRSS2-ERG gene fusion in prostate cancer YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines Prognostic outlier genes for enhanced prostate cancer treatment.Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1.Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy.Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer.Evaluating translocation gene fusions by SNP array data.5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer Oncogenic gene fusions in epithelial carcinomas Early human prostate adenocarcinomas harbor androgen-independent cancer cells Androgen receptor signaling in prostate cancer development and progression.Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells.TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features.Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer.ERG rearrangement as a novel marker for predicting the extra-prostatic extension of clinically localised prostate cancer.A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.Fusion in the ETS gene family and prostate cancer.The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.Common gene rearrangements in prostate cancer A sensitive array-based assay for identifying multiple TMPRSS2:ERG fusion gene variants.TMPRSS2-ETS fusion prostate cancer: biological and clinical implications.Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts.TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.ETS rearrangements in prostate cancer Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India.Is it important to decipher the heterogeneity of "normal karyotype AML"?Genetic variation in the upstream region of ERG and prostate cancer.Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men.The discovery and application of gene fusions in prostate cancer.Recurrent gene fusions in prostate cancer Translocations in epithelial cancers.

P2860

Q24647020-F92E07B0-67F9-4A5A-A07F-F13E1405DE6B Q24650647-A32F7DB3-5845-4FAC-849F-2551ECAAF72B Q26766271-45C5959A-B1ED-49A3-ABFD-C61943640BD2 Q26851525-05793443-8C54-45C5-8E80-E1A081DD9605 Q26997884-097F177F-E6D8-4F31-90B8-16F923A6867D Q28269156-3D43B258-7FD5-4EA4-B106-875468996D96 Q28477993-65AF416E-72B2-4FB9-9C69-273DF4282BF1 Q28771722-EDB5B3BA-A182-48BC-B0F0-2079316619E1 Q30244674-796959A2-0AD4-4E24-8E8B-89A8F569CC1F Q30427325-EB655A04-4578-408B-86F2-32C1AC2C779A Q33359279-FDC91DA7-A52C-4B23-84B0-6779CAF0643E Q33361134-D2EB6F31-341D-47A0-8843-CB6D0C4B8122 Q33594473-969DBC00-793B-4F40-B8B5-1963A07DCF6D Q34132911-FB5C8C1A-C470-44E2-BDF6-EC0A8671BCF5 Q34614232-B9A148F0-7ED5-42D6-B748-1483858512DF Q34949690-E79BD93C-FB15-48F7-AD8F-B364DCC404BD Q35005020-945A296C-98B4-482C-A394-22A9B92D4EF0 Q35183663-27DE0949-D98C-4597-ADF3-1AA1DE634FB6 Q35199287-0DB1C5EF-65D1-4102-BD5F-A89007F7B3E2 Q36147719-1A594316-74BE-45E1-954D-3BE50F02B4C8 Q36435777-10D62906-28F2-4594-86E5-E2D95AD56F98 Q36610777-4124FE64-592B-4247-A4B6-7C6D4920B644 Q36741911-173ECA1B-A748-4FB3-9093-F9040877E99D Q36784513-D48E8A1C-AD16-4533-8787-2638C50BEC35 Q36882701-69F99708-77DC-46C3-A97B-0B85FBAFF3CD Q36899790-2C4CBADC-012A-4335-AB24-9C65558538D0 Q36901964-F7D06131-CCF7-4351-B7FA-428F1B6632AC Q36920169-5318D316-AC3A-44AE-B578-CE1382C55591 Q36972104-C7429EDA-40AF-4749-B696-1724E0A97D45 Q36983532-EE8793F7-9484-4459-BD8D-83936B8747D6 Q37003441-449AC0A8-2FC5-49B7-A19B-C298B8C31A06 Q37046014-C7A921C4-2AEF-4E32-A533-82A9A5758738 Q37047029-7F93B189-EC29-4781-96EB-A3ED83A6B467 Q37054053-415F91DB-24CD-42F2-A649-815C17538891 Q37110802-D265B2A9-8EFF-4008-B744-44E8B827B3BC Q37127440-AC2ADBBA-D559-4AA3-AC4E-29E491197CCB Q37139054-AFD48E58-5652-4CBE-A0AF-005DED458F18 Q37142194-79B1B867-030C-42B5-A8E8-0FF8E1147231 Q37194503-8B1DD5C9-4FDD-43D7-A1D5-F5F559EB93E0 Q37363960-A4A4BED2-E194-4857-AEBF-0C4722F944BE

P2860

Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.

http://www.wikidata.org/entity/Q40685677

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Frequency of the TMPRSS2:ERG g ...... fferentiated prostate cancers.

@en

type

label

Frequency of the TMPRSS2:ERG g ...... fferentiated prostate cancers.

@en

prefLabel

Frequency of the TMPRSS2:ERG g ...... fferentiated prostate cancers.

@en

P1433

Q40685677-5350DF34-9C6C-42E3-998C-035493275744

P1476

Q40685677-A0E5CE5F-1359-4649-9194-4BF6984DA04C

P2093

Q40685677-4302FE82-05E1-411A-9CAE-4172A5B29CE3

Q40685677-4DA38B59-3E93-465B-B6BB-2FA115F59922

Q40685677-6C583771-73DC-4866-89A5-8E75E9015A1B

Q40685677-706CF0C3-7C5F-4965-840E-8C72BAFDEC0E

Q40685677-8DB6EE54-84FF-48F0-B1DB-AA59BD1977C7

Q40685677-ADDC5FAD-74E0-40FF-908C-767ED11A03BC

Q40685677-B8A461C9-FCEF-47CD-B797-CFFA607E9BDB

Q40685677-BFA0FED4-BA75-4A6F-BA40-C1A5F2FFD172

Q40685677-C85243B6-4F68-44A2-AC79-8DCFD06BB04D

Q40685677-D642AFB0-14E0-47ED-873E-CE49BD9B27E3

P2860

Q40685677-0F14D3CD-8D7A-4F4A-B9E3-4F7314A284E0

Q40685677-0F236DBC-2FFA-4F2A-B47B-CD6EAEA6B678

Q40685677-2D942249-5113-46EC-AAF9-9061A66A7FD8

Q40685677-30D44A00-7B05-4F2D-9DA7-37777521DD23

Q40685677-34B9A974-B2BE-4DE2-B09B-A080615D155D

Q40685677-393A68F6-1FEF-4A86-A0C5-F3407C7AE94F

Q40685677-3F6911EC-8916-40B3-9D79-62231456F8D6

Q40685677-4AABB841-A8F5-4E07-80E4-EB13879619B0

Q40685677-4BA728BA-3BB1-4E87-8398-9B550D433B81

Q40685677-54DB1C90-ABD8-4384-8A44-1A3B4404E0F9

P304

Q40685677-78A4C62B-3972-4DAB-938A-13A01A0D06A4

P31

Q40685677-6EC47678-FD42-4721-A723-AFF30BE6F117

P356

Q40685677-6B161870-9B39-416F-9612-50136FE09362

P407

Q40685677-4F8E5AD9-E81B-41E8-9601-5BA396DA91EA

P433

Q40685677-E8F93CBF-F754-4342-BF28-F4E43DD4FE61

P478

Q40685677-23CABD93-4D9E-4202-939E-A20B02FA69AA

P577

Q40685677-FCF03AFD-DB1E-409E-BE53-149ABEEBDD18

P5875

Q40685677-C93A3F06-EB27-4507-9186-DDD411CC5F62

P698

Q40685677-669222AF-8404-4283-8ABD-4B73F4BFA219

P932

Q40685677-9AD7C99E-7EB9-4584-B0CC-264137205033

P356

JCP.2006.043810

P1433

Journal of Clinical Pathology

P1476

Frequency of the TMPRSS2:ERG g ...... fferentiated prostate cancers.

@en

P2093

Alessandro De Luca

http://www.w3.org/2001/XMLSchema#string

Antonio Hurtado-Coll

http://www.w3.org/2001/XMLSchema#string

Ashish B Rajput

http://www.w3.org/2001/XMLSchema#string

David G Huntsman

http://www.w3.org/2001/XMLSchema#string

Edward C Jones

http://www.w3.org/2001/XMLSchema#string

Jodie B Palmer

http://www.w3.org/2001/XMLSchema#string

Ladan Fazli

http://www.w3.org/2001/XMLSchema#string

Martin E Gleave

http://www.w3.org/2001/XMLSchema#string

Melinda A Miller

http://www.w3.org/2001/XMLSchema#string

Michael E Cox

http://www.w3.org/2001/XMLSchema#string

P2860

A novel zinc finger gene is fused to EWS in small round cell tumor

Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model

Cancer statistics, 2006

Chromosomal deletions and tumor suppressor genes in prostate cancer.

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome.

Chromosomal clues to the development of prostate tumors.

Molecular biology of progression of prostate cancer.

Molecular biology of the Ets family of transcription factors.

P304

1238-1243

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JCP.2006.043810

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6545428

http://www.w3.org/2001/XMLSchema#string

P698

17259299

http://www.w3.org/2001/XMLSchema#string

P932

2095486

http://www.w3.org/2001/XMLSchema#string